671 related articles for article (PubMed ID: 31046547)
21. A highly potent anti-VISTA antibody KVA12123 - a new immune checkpoint inhibitor and a promising therapy against poorly immunogenic tumors.
Iadonato S; Ovechkina Y; Lustig K; Cross J; Eyde N; Frazier E; Kabi N; Katz C; Lance R; Peckham D; Sridhar S; Talbaux C; Tihista I; Xu M; Guillaudeux T
Front Immunol; 2023; 14():1311658. PubMed ID: 38152397
[TBL] [Abstract][Full Text] [Related]
22. In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates.
Wang C; Thudium KB; Han M; Wang XT; Huang H; Feingersh D; Garcia C; Wu Y; Kuhne M; Srinivasan M; Singh S; Wong S; Garner N; Leblanc H; Bunch RT; Blanset D; Selby MJ; Korman AJ
Cancer Immunol Res; 2014 Sep; 2(9):846-56. PubMed ID: 24872026
[TBL] [Abstract][Full Text] [Related]
23. Structural and In Vitro Functional Analyses of Novel Plant-Produced Anti-Human PD1 Antibody.
Rattanapisit K; Phakham T; Buranapraditkun S; Siriwattananon K; Boonkrai C; Pisitkun T; Hirankarn N; Strasser R; Abe Y; Phoolcharoen W
Sci Rep; 2019 Oct; 9(1):15205. PubMed ID: 31645587
[TBL] [Abstract][Full Text] [Related]
24. A newly discovered PD-L1 B-cell epitope peptide vaccine (PDL1-Vaxx) exhibits potent immune responses and effective anti-tumor immunity in multiple syngeneic mice models and (synergizes) in combination with a dual HER-2 B-cell vaccine (B-Vaxx).
Guo L; Overholser J; Darby H; Ede NJ; Kaumaya PTP
Oncoimmunology; 2022; 11(1):2127691. PubMed ID: 36211807
[TBL] [Abstract][Full Text] [Related]
25. Programmed death 1 and its ligands do not limit experimental foreign antigen-induced immune complex glomerulonephritis.
Ooi JD; Li M; Kourkoutzelos K; Yagita H; Azuma M; Holdsworth SR; Kitching AR
Nephrology (Carlton); 2015 Dec; 20(12):892-8. PubMed ID: 26043977
[TBL] [Abstract][Full Text] [Related]
26. Generation of potent mouse monoclonal antibodies to self-proteins using T-cell epitope "tags".
Percival-Alwyn JL; England E; Kemp B; Rapley L; Davis NH; McCarthy GR; Majithiya JB; Corkill DJ; Welsted S; Minton K; Cohen ES; Robinson MJ; Dobson C; Wilkinson TC; Vaughan TJ; Groves MA; Tigue NJ
MAbs; 2015; 7(1):129-37. PubMed ID: 25523454
[TBL] [Abstract][Full Text] [Related]
27. Drug-like antibodies with high affinity, diversity and developability directly from next-generation antibody libraries.
Azevedo Reis Teixeira A; Erasmus MF; D'Angelo S; Naranjo L; Ferrara F; Leal-Lopes C; Durrant O; Galmiche C; Morelli A; Scott-Tucker A; Bradbury ARM
MAbs; 2021; 13(1):1980942. PubMed ID: 34850665
[TBL] [Abstract][Full Text] [Related]
28. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
[TBL] [Abstract][Full Text] [Related]
29. A T-cell-dependent antibody response study using a murine surrogate anti-PD-1 monoclonal antibody as an alternative to a non-human primate model.
Plitnick LM; Hutchins B; Dubey S; Li N; Amin RP; Born S; Mangadu R; Phillips JH; Sriram V; Herzyk DJ
J Immunotoxicol; 2020 Dec; 17(1):175-185. PubMed ID: 33078980
[TBL] [Abstract][Full Text] [Related]
30. Chickens with humanized immunoglobulin genes generate antibodies with high affinity and broad epitope coverage to conserved targets.
Ching KH; Collarini EJ; Abdiche YN; Bedinger D; Pedersen D; Izquierdo S; Harriman R; Zhu L; Etches RJ; van de Lavoir MC; Harriman WD; Leighton PA
MAbs; 2018 Jan; 10(1):71-80. PubMed ID: 29035625
[TBL] [Abstract][Full Text] [Related]
31. [Efficacy of PD-1/PD-L1 immune checkpoint inhibitors and PD-L1 testing in thoracic cancers].
Duruisseaux M; Rouquette I; Adam J; Cortot A; Cazes A; Gibault L; Damotte D; Lantuejoul S
Ann Pathol; 2017 Feb; 37(1):61-78. PubMed ID: 28162296
[TBL] [Abstract][Full Text] [Related]
32. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations.
Vafa O; Gilliland GL; Brezski RJ; Strake B; Wilkinson T; Lacy ER; Scallon B; Teplyakov A; Malia TJ; Strohl WR
Methods; 2014 Jan; 65(1):114-26. PubMed ID: 23872058
[TBL] [Abstract][Full Text] [Related]
33. Antibody repertoire analysis of mouse immunization protocols using microfluidics and molecular genomics.
Asensio MA; Lim YW; Wayham N; Stadtmiller K; Edgar RC; Leong J; Leong R; Mizrahi RA; Adams MS; Simons JF; Spindler MJ; Johnson DS; Adler AS
MAbs; 2019 Jul; 11(5):870-883. PubMed ID: 30898066
[TBL] [Abstract][Full Text] [Related]
34. Roles of programmed death-1 (PD-1)/PD-1 ligands pathway in the development of murine acute myocarditis caused by coxsackievirus B3.
Seko Y; Yagita H; Okumura K; Azuma M; Nagai R
Cardiovasc Res; 2007 Jul; 75(1):158-67. PubMed ID: 17434153
[TBL] [Abstract][Full Text] [Related]
35. Development and characterization of monoclonal antibodies against canine PD-1 and PD-L1.
Nemoto Y; Shosu K; Okuda M; Noguchi S; Mizuno T
Vet Immunol Immunopathol; 2018 Apr; 198():19-25. PubMed ID: 29571514
[TBL] [Abstract][Full Text] [Related]
36. Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma.
Prat A; Navarro A; Paré L; Reguart N; Galván P; Pascual T; Martínez A; Nuciforo P; Comerma L; Alos L; Pardo N; Cedrés S; Fan C; Parker JS; Gaba L; Victoria I; Viñolas N; Vivancos A; Arance A; Felip E
Cancer Res; 2017 Jul; 77(13):3540-3550. PubMed ID: 28487385
[TBL] [Abstract][Full Text] [Related]
37. Rare, high-affinity mouse anti-PD-1 antibodies that function in checkpoint blockade, discovered using microfluidics and molecular genomics.
Adler AS; Mizrahi RA; Spindler MJ; Adams MS; Asensio MA; Edgar RC; Leong J; Leong R; Johnson DS
MAbs; 2017; 9(8):1270-1281. PubMed ID: 28846506
[TBL] [Abstract][Full Text] [Related]
38. Preclinical development of the TLR9 agonist DV281 as an inhaled aerosolized immunotherapeutic for lung cancer: Pharmacological profile in mice, non-human primates, and human primary cells.
Kell SA; Kachura MA; Renn A; Traquina P; Coffman RL; Campbell JD
Int Immunopharmacol; 2019 Jan; 66():296-308. PubMed ID: 30502651
[TBL] [Abstract][Full Text] [Related]
39. A New Strategy Toward B Cell-Based Cancer Vaccines by Active Immunization With Mimotopes of Immune Checkpoint Inhibitors.
Tobias J; Battin C; De Sousa Linhares A; Lebens M; Baier K; Ambroz K; Drinić M; Högler S; Inic-Kanada A; Garner-Spitzer E; Preusser M; Kenner L; Kundi M; Zielinski CC; Steinberger P; Wiedermann U
Front Immunol; 2020; 11():895. PubMed ID: 32528470
[TBL] [Abstract][Full Text] [Related]
40. [Development of IgHV family specific nucleic acid vaccine against lymphoma by construction of fusion gene of immunoglobulin heavy chain variable region and cytokine].
Liu H; Zhu P; Lin NJ; Zhang Y; Bu DF; Wang YJ; Wang YQ; Yang Y
Zhonghua Yi Xue Za Zhi; 2004 Jan; 84(1):48-53. PubMed ID: 14990159
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
